Biocon gains 'IND A1+' rating amidst positive biosimilar developments

Biocon has announced a series of strategic developments, including securing an "IND A1+" credit rating from India Ratings and Research for its INR12 billion Commercial Paper Program, underscoring the company's solid financial standing. This positive assessment arrives in tandem with advancements in Biocon Biologics’ biosimilar pipeline, most notably the agreement reached with Regeneron allowing for the commercialization of Yesafili™ (aflibercept-jbvf) in the United States. This interchangeable biosimilar to Eylea® is set to launch in the second half of 2026, or earlier under certain circumstances, marking a significant milestone for Biocon's strategic entry into the U.S. ophthalmology market. YESAFILI is intended for the treatment of neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV). These developments, highlighted by Biocon's management, reflect the company's commitment to expanding access to affordable, high-quality biosimilars and reinforcing its financial health.